ACR 2008 Video

Sunday, October 26, 2008
Cardiovascular Disease in Rheumatoid Arthritis
	Myocardial Infarction in Rheumatoid Arthritis: The Effects of DMARDs and Prednisolone Christopher J. Edwards, MD, FRCP Southampton University Hospitals NHS Trust, Southampton, UK
	Diastolic Dysfunction in Rheumatoid Arthritis Patients Kimberly P. Liang, MD Mayo Clinic, Rochester, Minnesota
	Increased Mortality after Acute Myocardial Infarction among Patients with Rheumatoid Arthritis Hilal Maradit Kremers, MD Mayo Clinic, Rochester, Minnesota
	Rheumatoid Arthritis As Important Independent Risk Factor For Incident Cardiovascular Disease Michael T. Nurmohamed, MD, PhD VU University Medical Center, Amsterdam, Netherlands
Innovative Metabolic Bone Disease
	Tai Chi is Effective in Treating Knee Osteoarthritis: A Randomized Controlled Trial Chenchen Wang, MD Tufts Medical Center, Boston, Massachusetts
	Tanezumab Relieves Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee: A Phase 2 Trial Nancy E. Lane, MD University of California at Davis Medical Center, Sacramento, California
	Teriparatide versus Alendronate for Treatment of Glucocorticoid- Induced Osteoporosis: 36-month Results Kenneth G. Saag, MD, MSc University of Alabama at Birmingham, Birmingham, Alabama
	Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate (Fosamax®) C. Deal, MD Cleveland Clinic, Cleveland, Ohio
	Efficacy and Safety of Intravenous (IV) Pegloticase (PGL) in Subjects with Treatment Failure Gout (TFG): Phase 3 Results from GOUT1 and GOUT2 J. S. Sundy, MD, PhD Duke University Medical Center, Durham, North Carolina

Monday, October 27, 2008
Biologics in RA
	Safety Data from Over 1,200 Patients-years of Methotrexate and/or Etanercept Treatment in Children with Polyarticular or Systemic Juvenile Rheumatoid Arthritis Norman T. Ilowite, MD Einstein College of Medicine, Bronx, New York
	Is The Exposure To TNF Antagonists A Risk Factor For Cancer In Rheumatoid Arthritis? Loreto Carmona, MD, PhD Fundacion Espanola de Reumatologia, Madrid, Spain
	Gene Expression Profiling of Rheumatoid Arthritis Patients Treated with Anti-Tumour Necrosis Factor Marieke J.H. Coenen, PhD Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
	Treatment of Rheumatoid Arthritis (RA) with a Syk Kinase Inhibitor: A 12 week randomized placebo controlled study Michael E. Weinblatt, MD Brigham & Women's Hospital, Boston, Massachusetts
Therapeutics: For the Young and Young at Heart
	A multicentric, double-blind trial of Anakinra versus placebo in Systemic Onset Juvenile Idiopathic Arthritis (ANAJIS trial): efficacy and tolerance over 12 months Pierre Quartier, MD Hopital Necker-Enfants Malades, Paris, France
	Reduction in Missed School Days and Improvement in Parent Activity Participation in Children with Juvenile Idiopathic Arthritis Treated with Abatacept Tracy Li, PhD Bristol-Myers Squibb, Princeton, New Jersey
	Protective Effect of Hydroxychloroquine (HCQ) on Renal Damage in Patients with Systemic Lupus Erythematosus (SLE): Data from a Multiethnic Cohort Graciela S. Alarcón, MD, MPH University of Alabama at Birmingham, Birmingham, Alabama
	Hydroxychloroquine Use Reduces Risk Of Diabetes In Rheumatoid Arthritis Patients Androniki Bili, MD, MPH Geisinger Medical Center, Danville, Pennsylvania
	Efficacy of Tadalafil in Secondary Raynaud's Phenomenon Resistant to Vasodilator Therapy: A Double Blind Randomized Cross Over Trial Padmanabha Shenoy, MBBS, MD Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

The videos require the Flash player to view, download and install the Flash Player.

• ACR 2008 Video: Interviews
• ACR 2008 News